Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susanne Hedbom

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Praxis|November 25, 2020
[Advanced Disease Situations with Organic Brain Changes]Susanne Hedbom, Sereina Catschegn
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2008
Phase I dose escalation and pharmacokinetic study of BI 2536, a novel Polo-like kinase 1 inhibitor, in patients with advanced solid tumorsKlaus Mross, Annette Frost, Simone Steinbild, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2012
A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumorsKlaus Mross, Annette Frost, Simone Steinbild, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Praxis|November 25, 2020
[Advanced Disease Situations with Organic Brain Changes]Susanne Hedbom, Sereina Catschegn
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2008
Phase I dose escalation and pharmacokinetic study of BI 2536, a novel Polo-like kinase 1 inhibitor, in patients with advanced solid tumorsKlaus Mross, Annette Frost, Simone Steinbild, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2012
A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumorsKlaus Mross, Annette Frost, Simone Steinbild, et al.
Pageof 1